Article Text

PDF
OC-037 6 year disease durability outcomes on patients treated with endoscopic therapy for barrett’s related neoplasia from the uk registry
  1. R Haidry1,2,
  2. G Lipman1,2,
  3. A Gupta1,
  4. J Dunn3,
  5. H Smart4,
  6. P Bhandari5,
  7. R Willert6,
  8. G Fullarton7,
  9. M di Pietro8,
  10. C Gordon9,
  11. I Penman10,
  12. P Boger11,
  13. N Ravi12,
  14. Y Ang13,
  15. M Novelli14,
  16. LB Lovat1,2
  17. and On behalf of the UK RFA registry
  1. 1Gastroenterology, UCLH
  2. 2National Medical Laser Centre, UCL
  3. 3GSTT, London
  4. 4RLBUHT, Liverpool
  5. 5PAH, Portsmouth
  6. 6CMFT, Manchester
  7. 7Glasgow Royal Infirmary, Glasgow
  8. 8Addenbrookes Hospital, Cambridge
  9. 9Royal Bournemouth Hospital, Bournemouth
  10. 11Southampton University Hospital, Southampton, UK
  11. 12St James Hospital, Dublin, Ireland
  12. 13SRFT, Manchester
  13. 14Histopathology, UCL, London, UK
  14. 10Royal Infirmary Edinburgh, Edinburgh

Abstract

Introduction Endoscopic therapy with combined Endoscopic mucosal resection (EMR) followed by Radiofrequency ablation (RFA) is now the recommended first line treatment for patients with Barrett’s (BE) related neoplasia confined to the oesophageal mucosa.

Method We examine prospective data from the United Kingdom registry of patients undergoing RFA/EMR for BE neoplasia since 2008.

Before RFA, visible lesions and nodularity were entirely removed by EMR. Thereafter patients underwent RFA 3 monthly until all visible BE was ablated or cancer developed (endpoints). Biopsies were taken at 12 months or when endpoints reached. Follow up endoscopies were performed periodically in all patients to check for recurrences thereafter.

All patients who had completed at least 12 months of follow up after successful treatment were included in the analysis to examine durability of disease reversal long term.

Results 282 patients (81% male, mean age 70 years) have completed the 12 month treatment protocol with a minimum of 12 months follow up thereafter. At median follow up of 37 months (IQR 29–49), 93% of patients with successful disease reversal were still free of neoplasia and 88% free of intestinal metaplasia recurrence. Cancer progression at this same time was seen in 1.4% of patients. Kaplan Meier (KM) statistics demonstrated a predicted 3 year neoplasia free survival in 88% of patients. At 5 and 6 years this was 86%. Similarly KM analysis showed that at 3 years 81% of patients would be free form BE and at 5 and 6 years this figure was 73%.

Conclusion We report long term outcomes of a large cohort of patients with BE neoplasia who have had successful endoscopic therapy with RFA/EMR. This approach appears to have a lasting disease free benefit in the majority of patients. Recurrences do occur in a minority of patients and highlights the need for follow up in those fit for endoscopy.

All collaborators of the UK RFA registry are acknowledged for their contributions to data collection for this work.

Disclosure of interest None Declared.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.